RxDoctor Payments Data

Vania Arroyo

Physician Assistant · la Jolla, CANPI 1043833163

Payments from drug & device makers

$2,935in general payments, 2019–2025

Across 134 payments — averaging $21.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$460
  • Daiichi Sankyo Inc.$366
  • Viiv Healthcare Company$298
  • Novo Nordisk$265
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$246
  • Stryker$165
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$2,935100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,935 in reported general payments places this provider in the 85th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$15,522
Medicare patients
65
Services billed
208

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide12$12,445
EliquisApixaban17$9,313
YuvafemEstradiol11$1,998
Wixela InhubFluticasone Propion/Salmeterol17$1,517
Atorvastatin Calcium62$888
Amlodipine-OlmesartanAmlodipine Bes/Olmesartan Med22$771
Albuterol Sulfate HfaAlbuterol Sulfate19$573
Rosuvastatin Calcium37$464
Lisinopril38$362
Gabapentin16$316
Fluticasone Propionate32$284
Amlodipine Besylate42$278
Levothyroxine Sodium15$229
Acetaminophen-CodeineAcetaminophen With Codeine12$211
Alendronate Sodium26$185

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$52$12,44512 claims
PfizerEliquis$53$9,31317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,423 physician assistant providers in California.

Other physician assistant in la Jolla

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →